StockNews.AI
ERNA
StockNews.AI
41 days

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

1. Ernexa Therapeutics regained compliance with Nasdaq listing requirements. 2. The company plans to initiate its first clinical trial in early 2026. 3. Ernexa focuses on cell therapies for advanced cancer and autoimmune diseases. 4. ERNA-101 targets ovarian cancer, leveraging engineered iPSCs technology. 5. Management emphasizes urgency in advancing treatment options for patients.

5m saved
Insight
Article

FAQ

Why Bullish?

Regaining compliance positively reflects management's performance, boosting investor confidence. Historical examples show stocks often rally after compliance news.

How important is it?

The article contains pivotal information about compliance and upcoming trials, directly influencing ERNA's investor outlook.

Why Short Term?

The immediate news of compliance and clinical trials may attract short-term investor interest. Historically, announcements of trial beginnings can lead to increased trading volumes.

Related Companies

NDAQBMRNTSLX
CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) --  Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market. On July 1, 2025, the company received formal notice from Nasdaq stating that Ernexa has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) for continued listing. “We remain laser-focused on advancing our programs toward the clinic, and we are on track to initiate our first clinical trial in early 2026,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “Our team continues to execute with discipline and urgency – for the sake of the many patients living with ovarian cancer and autoimmune disease and their loved ones. We believe that our novel approach to engineered cell therapies holds significant promise for patients with serious and underserved conditions.” About Ernexa Therapeutics Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting. ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer. For more information, visit www.ernexatx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law. Media & Investor Relations Contact investors@ernexatx.com

Related News